Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04291703 · ClinicalTrials.gov registry record · Phase 2
STOP-T1D Low-Dose (ATG)
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04291703 is a Phase 2 study that was terminated before completion, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 2 participants.
The verdict
NCT04291703, a Phase 2 study, was terminated before completion, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D. This study did not meet enrollment targets and was terminated approximately 13 months after the first participant enrolled.
Interventions
- DRUG Antithymocyte Globulin
- DRUG Placebo (for ATG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2024-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04291703
The ClinicalTrials.gov registry entry for NCT04291703 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Antithymocyte Globulin is the first listed.
NCT04291703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04291703 about?
NCT04291703 is a clinical study titled "STOP-T1D Low-Dose (ATG)". A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D. This study did not meet enrollment targets and was terminated approximately 13 months after the first participant...
What is the current status of trial NCT04291703?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2023-11-01. Estimated completion is 2024-12-17.
What interventions are being tested in trial NCT04291703?
The interventions under investigation include: Antithymocyte Globulin (DRUG), Placebo (for ATG) (DRUG).
Who is sponsoring clinical trial NCT04291703?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.